<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00061360</url>
  </required_header>
  <id_info>
    <org_study_id>030193</org_study_id>
    <secondary_id>03-H-0193</secondary_id>
    <nct_id>NCT00061360</nct_id>
  </id_info>
  <brief_title>Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia</brief_title>
  <official_title>A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized
      by pancytopenia and a hypocellular bone marrow. Allogeneic bone marrow transplantation and
      immunosuppressive treatment with anti-thymocyte globulin (ATG) and cyclosporine (CsA) have
      dramatically changed the natural course of this illness, with 5 year survival of 75% in
      patients undergoing either treatment. Since most patients are not suitable candidates for
      hematopoietic stem cell transplantation (HSCT) due to advanced age or lack of a
      histocompatible sibling, efforts at NHLBI have focused on improving immunosuppression
      treatment in order to improve response rates, survival, and to decrease relapse.

      In our experience of 122 patients treated at NHLBI with the combination of ATG and
      cyclosporine, one quarter to one third did not respond; about 50% of responders relapsed; and
      5 year survival was correlated with the robustness in blood cell count improvement at 3
      months (reticulocyte or platelet count greater than or equal to 50,000 /uL). Why some
      patients do not respond initially while others relapse is unclear. Autoreactive T cells may
      be resistant to the effect of ATG/CsA (nonresponders), while in others residual autoreactive
      T cells expand post-treatment leading to hematopoietic stem cell destruction and recurrent
      pancytopenia (relapse). Therefore, novel immunosuppressive regimens to increase response
      rates and hematologic recovery at 3 months and to decrease relapse rates are needed. An
      ongoing NHLBI trial, which is close to completing accrual, has added mycophenolate mofetil
      (MMF) for a total of 18 months to standard ATG + CsA in an attempt to reduce the relapse rate
      after cyclosporine is discontinued. Preliminary results have been disappointing, with no
      marked reduction in relapse among patients who received MMF.

      Sirolimus (rapamycin, Rapamune , RAPA) is a novel immunosuppressive agent, which acts
      synergistically with cyclosporine by blocking T cell activation through CsA-resistant
      pathways. The potentiation of the combination of CsA-RAPA has been established in vitro and
      in the clinical setting, mainly in islet cell and solid organ transplantation. The
      significant increase in response rate seen with the addition of CsA to ATG indicated that an
      inhibitory effect on T lymphocytes is important in blocking autoreactive T cells in aplastic
      anemia. The combination of CsA-RAPA may further block activated autoreactive T cells and
      therefore lead to improved response rates (and survival) and decreased relapse rates.

      This prospective randomized phase II study will investigate two different immunosuppressive
      regimens in patients with severe aplastic anemia who have not received prior
      immunosuppressive therapy. One arm will receive ATG + CsA in addition to sirolimus for 6
      months, and the second arm will receive standard ATG + CsA for 6 months followed by a slow
      taper of CsA with a 25% dose reduction every 3 months for the subsequent 18 months. This
      trial will determine the effectiveness of sirolimus in patients with aplastic anemia as well
      as the role of a cyclosporine taper in preventing relapses. Primary endpoint will be no
      longer meeting criteria for severe aplastic anemia while secondary endpoints are relapse,
      robustness of hematologic recovery at 3 months, survival, clonal evolution to PNH,
      myelodysplasia and acute leukemia.

      10/11/2005. The Sirolimus (Rapamune) arm of the trial was stopped for lack of efficacy. The
      study will continue as a single arm study to establish if slow taper of CsA prevents relapse
      rates after initial standard treatment with ATG followed by CsA for six months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized
      by pancytopenia and a hypocellular bone marrow. Allogeneic bone marrow transplantation and
      immunosuppressive treatment with anti-thymocyte globulin (ATG) and cyclosporine (CsA) have
      dramatically changed the natural course of this illness, with 5 year survival of 75% in
      patients undergoing either treatment. Since most patients are not suitable candidates for
      hematopoietic stem cell transplantation (HSCT) due to advanced age or lack of a
      histocompatible sibling, efforts at NHLBI have focused on improving immunosuppression
      treatment in order to improve response rates, survival, and to decrease relapse.

      In our experience of 122 patients treated at NHLBI with the combination of ATG and
      cyclosporine, one quarter to one third did not respond; about 50% of responders relapsed; and
      5 year survival was correlated with the robustness in blood cell count improvement at 3
      months (reticulocyte or platelet count greater than or equal to 50,000 /uL). Why some
      patients do not respond initially while others relapse is unclear. Autoreactive T cells may
      be resistant to the effect of ATG/CsA (nonresponders), while in others residual autoreactive
      T cells expand post-treatment leading to hematopoietic stem cell destruction and recurrent
      pancytopenia (relapse). Therefore, novel immunosuppressive regimens to increase response
      rates and hematologic recovery at 3 months and to decrease relapse rates are needed. An
      ongoing NHLBI trial, which is close to completing accrual, has added mycophenolate mofetil
      (MMF) for a total of 18 months to standard ATG + CsA in an attempt to reduce the relapse rate
      after cyclosporine is discontinued. Preliminary results have been disappointing, with no
      marked reduction in relapse among patients who received MMF.

      Sirolimus (rapamycin, Rapamune , RAPA) is a novel immunosuppressive agent, which acts
      synergistically with cyclosporine by blocking T cell activation through CsA-resistant
      pathways. The potentiation of the combination of CsA-RAPA has been established in vitro and
      in the clinical setting, mainly in islet cell and solid organ transplantation. The
      significant increase in response rate seen with the addition of CsA to ATG indicated that an
      inhibitory effect on T lymphocytes is important in blocking autoreactive T cells in aplastic
      anemia. The combination of CsA-RAPA may further block activated autoreactive T cells and
      therefore lead to improved response rates (and survival) and decreased relapse rates.

      This prospective randomized phase II study will investigate two different immunosuppressive
      regimens in patients with severe aplastic anemia who have not received prior
      immunosuppressive therapy. One arm will receive ATG + CsA in addition to sirolimus for 6
      months, and the second arm will receive standard ATG + CsA for 6 months followed by a slow
      taper of CsA with a 25% dose reduction every 3 months for the subsequent 18 months. This
      trial will determine the effectiveness of sirolimus in patients with aplastic anemia as well
      as the role of a cyclosporine taper in preventing relapses. Primary endpoint will be no
      longer meeting criteria for severe aplastic anemia while secondary endpoints are relapse,
      robustness of hematologic recovery at 3 months, survival, clonal evolution to PNH,
      myelodysplasia and acute leukemia.

      10/11/2005. The Sirolimus (Rapamune) arm of the trial was stopped for lack of efficacy. The
      study will continue as a single arm study to establish if slow taper of CsA prevents relapse
      rates after initial standard treatment with ATG followed by CsA for six months.

      3/2/2006. The protocol was closed to new accrual.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 23, 2003</start_date>
  <completion_date type="Actual">September 8, 2015</completion_date>
  <primary_completion_date type="Actual">May 31, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of new combined treatement of ATG, CsA and sirolimus versus standard ATG/CsA.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">77</enrollment>
  <condition>Aplastic Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus (Rapamune)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Severe aplastic anemia confirmed at NIH by:

          1. . Bone marrow cellularity less than 30% (excluding lymphocytes)

          2. . At least two of the following: Absolute neutrophil count less than 500/ uL; Platelet
             count less than 20,000/ uL; Absolute reticulocyte count less than 60,000/ uL

        Age greater than or equal to 2 years old

        Weight greater than 12 kg

        EXCLUSION CRITERIA:

        Serum creatinine greater than 2.5 mg/dL

        Underlying carcinoma (except local cervical, basal cell, squamous cell)

        Prior immunosuppressive therapy with ATG, ALG, or high dose cyclophospamide.

        Current pregnancy or lactation or unwillingness to take oral contraceptives or use an
        effective method of birth control.

        Diagnosis of Fanconi anemia or other congenital bone marrow failure syndromes

        Evidence of a clonal disorder on cytogenetics. Patients with super severe neutropenia (ANC
        less than 200/uL) will not be excluded if results of cytogenetics are not available or
        pending.

        Underlying immunodeficiency state including seropositivity for HIV

        Inability to understand the investigational nature of the study or give informed consent

        Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious,
        or metabolic disease of such severity that it would preclude the patient s ability to
        tolerate protocol therapy, or that death within 7-10 days is likely.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal S Young, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2003-H-0193.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Bacigalupo A, Brand R, Oneto R, Bruno B, Soci√© G, Passweg J, Locasciulli A, Van Lint MT, Tichelli A, McCann S, Marsh J, Ljungman P, Hows J, Marin P, Schrezenmeier H. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000 Jan;37(1):69-80. Review.</citation>
    <PMID>10676912</PMID>
  </reference>
  <reference>
    <citation>Young NS. Acquired aplastic anemia. Ann Intern Med. 2002 Apr 2;136(7):534-46. Review.</citation>
    <PMID>11926789</PMID>
  </reference>
  <reference>
    <citation>Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997 May 8;336(19):1365-72. Review.</citation>
    <PMID>9134878</PMID>
  </reference>
  <verification_date>August 16, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2003</study_first_submitted>
  <study_first_submitted_qc>May 23, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2003</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Marrow Failure</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Anti Thymocyte Globulin</keyword>
  <keyword>Severe Aplastic Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

